Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
about
A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosisSide chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.Clinical application of transcriptional activators of bile salt transporters.Alterations in xenobiotic metabolism in the long-lived Little mice.Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle.Ursodeoxycholic acid treatment of vanishing bile duct syndromes.Hepatocyte transplantation in bile salt export pump-deficient mice: selective growth advantage of donor hepatocytes under bile acid stress.Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice.Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene.The farnesoid X receptor: a novel drug target?Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice.Regulation of hepatic ABCC transporters by xenobiotics and in disease states.Cytokeratins as targets for bile acid-induced toxicity.Bile acid-induced Mallory body formation in drug-primed mouse liver.Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis.Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis.Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs.Transporters in the intestine limiting drug and toxin absorption.Ursodeoxycholic acid: Mechanism of action and novel clinical applications.Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ outputCurcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.Bile-acid-induced cell injury and protectionOST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids.Nuclear receptors as therapeutic targets in cholestatic liver diseases.The role of FXR in disorders of bile acid homeostasis.Role of hepatic transporters in prevention of bile acid toxicity after partial hepatectomy in mice.Regulation of hepatic bile acid transporters Ntcp and Bsep expression.Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver diseaseUrsodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.Bile acid transporters and regulatory nuclear receptors in the liver and beyondEvaluation of transcriptomic signature as a valuable tool to study drug-induced cholestasis in primary human hepatocytes.Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters.Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis.Severe acute cholestatic hepatitis of unknown etiology successfully treated with the Chinese herbal medicine Inchinko-to (TJ-135).Strong activation of bile acid-sensitive ion channel (BASIC) by ursodeoxycholic acid.Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis.Treatment for tuberculosis in a patient with Dubin-Johnson syndrome.Inhibition of nitric oxide synthesis during induced cholestasis ameliorates hepatocellular injury by facilitating S-nitrosothiol homeostasis.
P2860
Q30479829-49EFD444-5990-452C-9E7B-FD6BA584409FQ30535328-21544384-473A-4A7C-9C07-E3DEB6CE23A0Q33709930-9A279976-94C2-445E-AE55-48F19268CAD9Q33809704-D156CD64-9C8F-4CFA-87AE-FEC1E31D12F6Q33811333-96F4EE15-0B0F-4420-9370-45489AA3D7BBQ33866782-9D5E835F-8A46-4B4A-AA34-531BFA3177E9Q33985967-1EA8E3DE-28C2-4F8D-903D-B1B007E51FA1Q34017604-B8A09727-8B74-499F-8D65-4B41A3D08148Q34037360-2C8C335D-1F13-4B5E-8521-470532C4A1AFQ34287166-8CF64115-28DB-4136-84C4-19A298A52A64Q34343494-EBC6E872-1C18-47CB-962C-BB91C4899E5BQ35087943-06989948-08DC-4F4B-BBEF-AA79BCF7B9B5Q35690177-C8EE3FD8-B200-450A-BA4C-D24BF811C519Q35747276-E8A8819B-2A6B-4194-9172-8C2FF7879D1BQ35748180-CE4D17D4-6AE2-4580-AAEB-DA4C86EC4F8AQ36495172-3203E47F-7F9F-4A98-89D4-79B874128C9FQ36527921-9ECE2F58-83A5-487B-A42B-2316361B670FQ36606886-A56BBCAF-19BC-47C0-9D82-AEBC044926DCQ36795136-E8EB2F4E-3B67-40BE-9CD1-258F077F9D94Q36920468-8897C00C-44B3-436F-89D3-825FA9D5858DQ37012207-B591C22F-3AE1-44CF-AF0E-03277187FF03Q37096585-3C43A780-555B-4851-AC5E-E9E9AC8512AFQ37130129-DF45CAC9-E640-40E6-8F7E-AE4E44F5634FQ37157813-B353E968-B329-465B-8B03-D79E9FBE47D3Q37222442-7ED14309-4DCD-4CE3-BC9A-E7621906CB94Q37230857-23F53E91-EDDD-4463-9073-3FAB00B2EF00Q37300843-0CC9A3DC-7F61-493B-BA35-D816C7D493A2Q37337714-293B9156-AAA1-40C4-8F14-4C0E0FD16A67Q37339863-1922260D-D736-4958-8553-B5D76ED35F88Q37699357-036770A1-B847-4FAA-B3E8-BF7496F0094AQ37919924-D6D94F72-4C18-4549-A456-4F1F311641BDQ38033967-CA4FF35F-93EA-4235-8687-1204409CA3ACQ38758672-1AA69B71-1876-41AE-AE79-F8D7F5DB487DQ39901207-2C6F3349-20B4-4ACC-986B-0396CEAB5B6AQ40183754-D90F3A0F-7E18-4E8B-9C29-E1C7E6368BB3Q41336547-0EDB5134-C397-42DD-9F97-A67BDAC78896Q41566502-B0CCF472-43B3-42DE-89FA-96A4F4E7414FQ41587167-CF1308A0-D4A1-4215-81A6-09C6AA2A762DQ42453825-0CA0D4CA-CC20-4F09-9011-E908C5AE0CD1Q43266690-6F79BF9F-F8D6-4CB2-9C30-938C5006527E
P2860
Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Effects of ursodeoxycholic and ...... ter expression in mouse liver.
@en
Effects of ursodeoxycholic and ...... ter expression in mouse liver.
@nl
type
label
Effects of ursodeoxycholic and ...... ter expression in mouse liver.
@en
Effects of ursodeoxycholic and ...... ter expression in mouse liver.
@nl
prefLabel
Effects of ursodeoxycholic and ...... ter expression in mouse liver.
@en
Effects of ursodeoxycholic and ...... ter expression in mouse liver.
@nl
P2093
P356
P1433
P1476
Effects of ursodeoxycholic and ...... ter expression in mouse liver.
@en
P2093
Fuchsbichler A
Stumptner C
Zatloukal K
P304
P356
10.1053/GAST.2001.25542
P407
P577
2001-07-01T00:00:00Z